Study termination [Regulatives / Guidelines]

posted by anky1212 – India, 2013-05-08 20:18 (4797 d 00:18 ago) – Posting: # 10555
Views: 3,124

Dear All

Please give your views in the following case:

If in period-1 of bio-study, out of 36 subjects, 13 subjects withdrawn due to Pharmacokinetic reasons (due to AE of vomiting) but not any serious safety issues;
  1. If power of study reduces to very large extent, study will not pass as per regulatory requirement.Would it be ethical to conduct second period?

  2. If study is to be terminated, is it required to submit termination report to DCGI? And if study for US regulatory, is it required to submit termination report to USFDA?

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
385 visitors (0 registered, 385 guests [including 13 identified bots]).
Forum time: 20:36 CEST (Europe/Vienna)

Ignorance more frequently begets confidence
than does knowledge.    Charles Darwin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5